Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

Related Articles by Review for PubMed (Select 19307500)

1.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ.

J Clin Oncol. 2009 May 1;27(13):2231-7. doi: 10.1200/JCO.2008.20.0238. Epub 2009 Mar 23.

2.
3.

Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.

Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, Wu XY, Huang YF, Mao C, Tang JL.

PLoS One. 2013;8(3):e57528. doi: 10.1371/journal.pone.0057528. Epub 2013 Mar 5. Review.

4.

Recent updates on the role of chemotherapy in pancreatic cancer.

Burris HA 3rd.

Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3. Review.

PMID:
16143160
5.

New directions in the management of advanced pancreatic cancer: a review.

Rocha-Lima CM.

Anticancer Drugs. 2008 Jun;19(5):435-46. doi: 10.1097/CAD.0b013e3282fc9d11. Review.

PMID:
18418211
6.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

7.

Her signaling in pancreatic cancer.

Burtness B.

Expert Opin Biol Ther. 2007 Jun;7(6):823-9. Review.

PMID:
17555368
8.

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

Rivera F, López-Tarruella S, Vega-Villegas ME, Salcedo M.

Cancer Treat Rev. 2009 Jun;35(4):335-9. doi: 10.1016/j.ctrv.2008.11.007. Epub 2009 Jan 7. Review.

PMID:
19131170
9.

Novel advances in pancreatic cancer treatment.

Vulfovich M, Rocha-Lima C.

Expert Rev Anticancer Ther. 2008 Jun;8(6):993-1002. doi: 10.1586/14737140.8.6.993. Review.

PMID:
18533808
10.

New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.

Burris H 3rd, Rocha-Lima C.

Oncologist. 2008 Mar;13(3):289-98. doi: 10.1634/theoncologist.2007-0134. Review.

11.

[Medical-oncological aspects in the treatment of pancreatic cancer].

Heinemann V.

Radiologe. 2009 Feb;49(2):144-8. doi: 10.1007/s00117-008-1753-3. Review. German.

PMID:
19048221
12.

Metastatic pancreatic cancer: old drugs, new paradigms.

Conroy T, Gavoille C, Adenis A.

Curr Opin Oncol. 2011 Jul;23(4):390-5. doi: 10.1097/CCO.0b013e3283473610. Review.

PMID:
21505335
13.

Pancreatic cancer: an update.

Kindler HL.

Curr Oncol Rep. 2007 May;9(3):170-6. Review.

PMID:
17430687
14.

Treatment of metastatic pancreatic adenocarcinoma: a review.

Thota R, Pauff JM, Berlin JD.

Oncology (Williston Park). 2014 Jan;28(1):70-4. Review.

15.

Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Ying JE, Zhu LM, Liu BX.

World J Gastroenterol. 2012 Feb 28;18(8):736-45. doi: 10.3748/wjg.v18.i8.736. Review.

16.

Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.

Li Q, Yuan Z, Yan H, Wen Z, Zhang R, Cao B.

Clin Ther. 2014 Jul 1;36(7):1054-63. doi: 10.1016/j.clinthera.2014.05.066. Epub 2014 Jun 27. Review.

PMID:
24986485
17.

Monoclonal antibodies and other targeted therapies for pancreatic cancer.

Cinar P, Tempero MA.

Cancer J. 2012 Nov-Dec;18(6):653-64. doi: 10.1097/PPO.0b013e3182758985. Review.

PMID:
23187854
18.

Cytotoxic therapy for advanced pancreatic adenocarcinoma.

O'Reilly EM, Abou-Alfa GK.

Semin Oncol. 2007 Aug;34(4):347-53. Review.

PMID:
17674963
19.

Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.

Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M.

Cancer Treat Rev. 2014 Feb;40(1):118-28. doi: 10.1016/j.ctrv.2013.04.004. Epub 2013 Jul 9. Review.

PMID:
23849556
20.

[Treatment of advanced pancreatic carcinoma].

Höhler T, Staib L, Oettle H.

Onkologie. 2008;31 Suppl 5:29-31. doi: 10.1159/000163074. Epub 2008 Nov 14. Review. German.

PMID:
19033702
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk